News of Note—Sanofi, GlaxoSmithKline's 2017 vaccine sales and more

In this week's news of note, Sanofi and GlaxoSmithKline reported vaccines sales growth. (Pixabay)

Here is some other vaccine news of note for the week:

> Sanofi delivered vaccine sales growth of 8.3% to $6.29 billion for 2017, driven primarily by travel and other endemics vaccines. Release

> GlaxoSmithKline's vaccine sales grew 6% last year to $7.24 billion. Release

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.

> Médecins Sans Frontières is taking a patent battle against Pfizer's Prevnar 13 to the Supreme Court of South Korea. Release

> The CDC has released new recommended immunization schedules for adults and children. Changes include recommending GlaxoSmithKline’s recombinant zoster vaccine Shingrix over Merck & Co.’s Zostavax for adults 50 or older. Children advisory | Adult advisory 

> U.S. Sen. Edward Markey, D-Mass., is calling on the country to spend $1 billion to develop a universal flu vaccine. Associated Press article

> Vaxart said its oral flu vaccine significantly reduced influenza infections compared with an approved quadrivalent influenza vaccine in a phase 2 challenge study. Release